Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1975 1
1976 2
1977 1
1978 3
1979 3
1980 3
1981 3
1982 4
1983 5
1984 5
1985 7
1986 7
1987 6
1988 6
1989 13
1990 12
1991 10
1992 20
1993 10
1994 13
1995 20
1996 12
1997 20
1998 29
1999 20
2000 13
2001 12
2002 13
2003 29
2004 20
2005 33
2006 33
2007 34
2008 34
2009 32
2010 39
2011 33
2012 42
2013 47
2014 68
2015 71
2016 70
2017 66
2018 88
2019 80
2020 83
2021 88
2022 82
2023 83
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

1,261 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypertrophic cardiomyopathy 16"
Page 1
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, Hegde SM, Jacoby D, Lakdawala NK, Lester SJ, Ma Y, Marian AJ, Nagueh SF, Owens A, Rader F, Saberi S, Sehnert AJ, Sherrid MV, Solomon SD, Wang A, Wever-Pinzon O, Wong TC, Heitner SB. Ho CY, et al. J Am Coll Cardiol. 2020 Jun 2;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064. J Am Coll Cardiol. 2020. PMID: 32466879 Free article. Clinical Trial.
BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies. ...(A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertroph …
BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; howeve …
Diagnostic yield of genetic testing in a heterogeneous cohort of 1376 HCM patients.
Hathaway J, Heliö K, Saarinen I, Tallila J, Seppälä EH, Tuupanen S, Turpeinen H, Kangas-Kontio T, Schleit J, Tommiska J, Kytölä V, Valori M, Muona M, Sistonen J, Gentile M, Salmenperä P, Myllykangas S, Paananen J, Alastalo TP, Heliö T, Koskenvuo J. Hathaway J, et al. BMC Cardiovasc Disord. 2021 Mar 5;21(1):126. doi: 10.1186/s12872-021-01927-5. BMC Cardiovasc Disord. 2021. PMID: 33673806 Free PMC article.
BACKGROUND: Genetic testing in hypertrophic cardiomyopathy (HCM) is a published guideline-based recommendation. ...Two percent of diagnostic variants were in genes associated with a cardiomyopathy other than HCM or an inherited arrhythmia. Clinical variables …
BACKGROUND: Genetic testing in hypertrophic cardiomyopathy (HCM) is a published guideline-based recommendation. ...Two percent …
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Desai MY, Owens A, Geske JB, Wolski K, Saberi S, Wang A, Sherrid M, Cremer PC, Naidu SS, Smedira NG, Schaff H, McErlean E, Sewell C, Balasubramanyam A, Lampl K, Sehnert AJ, Nissen SE. Desai MY, et al. Circulation. 2023 Mar 14;147(11):850-863. doi: 10.1161/CIRCULATIONAHA.122.062534. Epub 2022 Nov 6. Circulation. 2023. PMID: 36335531 Clinical Trial.
BACKGROUND: Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults with Symptomatic O …
BACKGROUND: Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy …
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).
O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. O'Mahony C, et al. Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14. Eur Heart J. 2014. PMID: 24126876
AIMS: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. ...The calibration slope was 0.91 (95% CI: 0.74, 1.08), C-index was 0.70 (95% CI: 0.68, 0.72), and D-statistic was 1.07 (95% CI: 0.81, 1.32). For every 16 …
AIMS: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. ...The calibration s …
Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy.
Liu J, Zhao S, Yu S, Wu G, Wang D, Liu L, Song J, Zhu Y, Kang L, Wang J, Song L. Liu J, et al. Radiology. 2022 Feb;302(2):298-306. doi: 10.1148/radiol.2021210914. Epub 2021 Nov 2. Radiology. 2022. PMID: 34726536
Background Myocardial replacement fibrosis is one of the major histologic features of hypertrophic cardiomyopathy (HCM), but its characteristics have not been well delineated. ...Cox analysis indicated that both the global extent of LGE (adjusted hazard ratio = 1.68 …
Background Myocardial replacement fibrosis is one of the major histologic features of hypertrophic cardiomyopathy (HCM), but i …
Hypertrophic cardiomyopathy: etiology, diagnosis, and treatment.
Ramaraj R. Ramaraj R. Cardiol Rev. 2008 Jul-Aug;16(4):172-80. doi: 10.1097/CRD.0b013e318178e525. Cardiol Rev. 2008. PMID: 18562807 Review.
Hypertrophic cardiomyopathy (HCM) is a disease characterized by primary hypertrophy of the left (and sometimes right) ventricle. ...
Hypertrophic cardiomyopathy (HCM) is a disease characterized by primary hypertrophy of the left (and sometimes right) ventricl …
Hypertrophic Cardiomyopathy and Sudden Death Initially Identified at Autopsy.
Maron BJ, Mackey-Bojack S, Facile E, Duncanson E, Rowin EJ, Maron MS. Maron BJ, et al. Am J Cardiol. 2020 Jul 15;127:139-141. doi: 10.1016/j.amjcard.2020.04.021. Epub 2020 Apr 23. Am J Cardiol. 2020. PMID: 32375998 Review.
Hypertrophic cardiomyopathy (HC) is associated with a well-recognized risk for unexpected sudden death (SD). ...Paul, Minnesota), we studied 86 selected heart specimens from young HC patients who died suddenly and unexpectedly without prior clinical evaluation, ages …
Hypertrophic cardiomyopathy (HC) is associated with a well-recognized risk for unexpected sudden death (SD). ...Paul, Minnesot …
Hypertrophic cardiomyopathy with latent obstruction: Clinical characteristics and surgical results.
Ji Q, Wang Y, Liu F, Yang Y, Xia L, Ding W, Lai H, Wang C. Ji Q, et al. J Cardiol. 2022 Jan;79(1):42-49. doi: 10.1016/j.jjcc.2021.09.002. Epub 2021 Sep 20. J Cardiol. 2022. PMID: 34551867 Free article.
RESULTS: Comparatively, patients with latent obstruction were younger (51.612.1 years vs. 57.211.6 years, p=0.003) and had higher prevalence of mitral subvalvular abnormalities (73.3% vs. 16.2%, p<0.001) and basal variant of hypertrophic cardiomyopathy (84 …
RESULTS: Comparatively, patients with latent obstruction were younger (51.612.1 years vs. 57.211.6 years, p=0.003) and had higher prevalence …
Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
Farrant J, Dodd S, Vaughan C, Reid A, Schmitt M, Garratt C, Akhtar M, Mahmod M, Neubauer S, Cooper RM, Prasad SK, Singh A, Valkovič L, Raman B, Ashkir Z, Clayton D, Baroja O, Duran B, Spowart C, Bedson E, Naish JH, Harrington C, Miller CA; TEMPEST investigators. Farrant J, et al. Heart. 2023 Jul 12;109(15):1175-1182. doi: 10.1136/heartjnl-2022-322271. Heart. 2023. PMID: 37137675 Free PMC article. Clinical Trial.
AIMS: Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy (LVH), myocardial fibrosis, enhanced oxidative stress and energy depletion. ...METHODS: The Efficacy and Mechanism of Trientine in Patients with Hypertrophic Cardiomyo …
AIMS: Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy (LVH), myocardial fibrosis, enhanced …
Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy.
Norrish G, Cleary A, Field E, Cervi E, Boleti O, Ziółkowska L, Olivotto I, Khraiche D, Limongelli G, Anastasakis A, Weintraub R, Biagini E, Ragni L, Prendiville T, Duignan S, McLeod K, Ilina M, Fernandez A, Marrone C, Bökenkamp R, Baban A, Kubus P, Daubeney PEF, Sarquella-Brugada G, Cesar S, Klaassen S, Ojala TH, Bhole V, Medrano C, Uzun O, Brown E, Gran F, Sinagra G, Castro FJ, Stuart G, Yamazawa H, Barriales-Villa R, Garcia-Guereta L, Adwani S, Linter K, Bharucha T, Gonzales-Lopez E, Siles A, Rasmussen TB, Calcagnino M, Jones CB, De Wilde H, Kubo T, Felice T, Popoiu A, Mogensen J, Mathur S, Centeno F, Reinhardt Z, Schouvey S, Elliott PM, Kaski JP. Norrish G, et al. J Am Coll Cardiol. 2022 May 24;79(20):1986-1997. doi: 10.1016/j.jacc.2022.03.347. J Am Coll Cardiol. 2022. PMID: 35589160 Free PMC article.
BACKGROUND: Up to one-half of childhood sarcomeric hypertrophic cardiomyopathy (HCM) presents before the age of 12 years, but this patient group has not been systematically characterized. OBJECTIVES: The aim of this study was to describe the clinical presentation an …
BACKGROUND: Up to one-half of childhood sarcomeric hypertrophic cardiomyopathy (HCM) presents before the age of 12 years, but …
1,261 results